Imagine.
Today, we can easily get hold of data.
Customer data, patient data, real world data, benchmarking data.
Indeed, data is our ‘goldmine’.
It’s the future of our industry, according to Vas Naramishan, as he recently relaunched Novartis as a ‘medicine and data science company’.
But when Cambridge Analytica became news, and GDPR went live, data suddenly became more than just a commodity. It’s now something precious. Something more difficult to obtain.
Most now say that the tables have turned, and there is an inexorable rise in our personal quest for data privacy: so much so that soon we will begin treating data not just as something private, but as personal property. Belonging to the individual. Not ours.
If data becomes personal property, will that be a blessing or a curse for pharma? And industry in general? It’s a fascinating and potentially hugely impactful situation and it must be debated.
That’s why eyeforpharma is launching a new webinar (June 27th ,2PM BST) in order to explore how we will need to operate going forward, as data becomes something we increasingly have to earn. Joining us are some of pharma’s finest minds in data and blockchain technology.
Sign up for free now: https://goo.gl/9UyK3e
If you can’t make it on the day, sign up anyway and they’ll send you a recording afterwards.